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Exclusive Development of a Single Type of
Keratinocyte Skin Cancer: Evidence from an Australian
Population–Based Cohort Study
Ulrike Keim1,2, Jolieke C. van der Pols2,3, Gail M. Williams3 and Ade`le C. Green2,4
Whether susceptible people develop both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) or one
type exclusively during life is unknown. We investigated this in an Australian community cohort of 1,191 adults
aged 25–75 years by recording all new BCCs and SCCs for 16 years in people with no previous keratinocyte
cancer. Among those who developed multiple skin cancers, age- and sex-specific incidence rates per 100,000
were calculated for those who developed BCC exclusively, SCC exclusively, or BCC and SCC. Corresponding
relative risks (and 95% confidence intervals) were estimated by Poisson regression. During follow-up, 116 people
developed multiple keratinocyte cancers: 65 (56%) developed BCC exclusively (range 2–8 per person); 18 (16%)
developed SCC exclusively (2–5 per person); and 28% developed both types. Of the 116, 88 had a BCC first, of
whom 74% subsequently developed only BCCs, and 28 had SCC first, of whom 64% subsequently developed only
SCCs. Incidence rates did not differ by sex in the BCC-only, SCC-only, or mixed groups, but they increased
significantly with age especially in the SCC-only group. These findings suggest that the majority of people are
prone to develop one type rather than a mix of keratinocyte cancers.
Journal of Investigative Dermatology (2015) 135, 728–733; doi:10.1038/jid.2014.410; published online 16 October 2014
INTRODUCTION
Basal cell carcinoma (BCC) and squamous cell carcinoma
(SCC) impose a large burden of morbidity and cost on white-
skinned populations owing to their high incidence rates (IRs)
(Joseph et al., 2001; Housman et al., 2003; Mudigonda et al.,
2010). The burden also reflects patients’ tendency to develop
more than one primary keratinocyte cancer in their lifetime
(Karagas, 1994; Marcil and Stern, 2000; Flohil et al., 2011).
Anecdotal evidence from clinicians suggests that patients with
a first BCC often go on to develop more BCCs but no SCCs,
and those with a first SCC often subsequently develop only
SCCs. However, no epidemiologic studies to date appear to
have tracked patients’ entire skin cancer history and
documented the types of keratinocyte cancers they developed.
Several studies have assessed the proportion of people with a
second primary skin cancer who develop the same type as the
index skin cancer, whether BCC or SCC, and their findings have
been systematically reviewed (Flohil et al., 2013).On meta-
analysis, the pooled proportion of BCC patients who developed
a subsequent BCC was 29% compared with 4% developing a
subsequent SCC, whereas the pooled proportion of SCC
patients who developed a subsequent SCC was 13%
compared with 16% developing a subsequent BCC (Flohil
et al., 2013). When meta-analysis was restricted to patients
whose index skin cancer was their first, pooled proportions
were similar. Beyond this evidence, there has been a clinic-
based study of renal transplant recipients (Wisgerhof et al.,
2010) that reported that immunosuppressed patients also tend
to develop second skin cancers of the same type as the first:
BCC after BCC, and SCC after SCC. They recorded the
keratinocyte cancer type if a third cancer developed; how-
ever, full details were presented only for the first two. Thus, the
question of what proportions of people are prone to develop
exclusively BCC or exclusively SCC when they develop more
than one cancer during their life remains unanswered.
We sought to address this question by identifying people
who had no keratinocyte cancer history in a random sample of
the population, and then recording and classifying the types of
skin cancers that each newly affected person developed in the
next decade and a half. In particular, we aimed to assess
whether there were multiply affected individuals who devel-
oped only BCC and others who developed only SCCs, or
whether such people tended to develop a mix of both, in
proportion to background IRs according to age and sex. We
also assessed the relative anatomic site distributions of BCC
versus SCC among multiply affected people. Such knowledge
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can aid the understanding of the biology and epidemiology of
BCC and SCC, respectively, by showing how frequently they
occur in the same individual or even on the same body sites
within individuals.
RESULTS
Study population
From the original cohort of 1,621 people at study baseline
who took part in the Nambour skin cancer prevention trial
(conducted 1992–1996), 430 were excluded: 426 with
keratinocyte cancer before or at the start of the study in
1992 and 6 with non-Caucasian ethnicity. The sex distribu-
tion of those excluded from the analysis (55% women) did not
differ significantly (P¼0.20) from those included in the
analysis (57% women), but those excluded were significantly
older (Po0.001) with a mean age of 57 years. The final study
population comprised 1,191 participants (mean age 46 years)
who had never had keratinocyte skin cancer and who were
followed up for almost 16 years, from April 1992 to
December 2007, resulting in an observed 15,433 person-
years at risk (pyar) and a follow-up rate of 82%.
By the end of the follow-up period, 943 participants (79%)
remained lesion-free and 248 participants had developed a
first keratinocyte cancer. Of the 248 affected persons, 132
(53%) developed only one BCC or SCC and 116 (47%)
developed multiple lesions. Among those with multiple
lesions, 65 (56%) individuals were affected by BCCs only,
18 (16%) were affected by SCCs only, and 33 (28%) devel-
oped a mix of both BCC and SCC. Of those with exclusively
BCCs, 30 (46%) developed 2 BCCs; 32 (49%) developed 3–5
BCCs; and 3 (5%) developed 6–8 BCCs (and 2 developed a
primary melanoma). The median spacing between BCCs was
17.4 months (interquartile range (IQR) from 1.4 to 49.0
months). Among those with SCCs exclusively, nine (50%)
developed 2 SCCs and the other nine developed 3–5 SCCs
(and one developed a primary melanoma), with the median
interval between SCCs being 19.8 months (IQR 3.9–48.3).
Among the 33 who developed BCCs and SCCs, about a third
(36%, N¼12) developed one BCC and one SCC and the
remainder (64%, N¼21) developed a mixed range of 3–8
lesions per person (no melanomas). For the mixed group,
median interval between BCCs was 9.0 months (IQR 1.1–
28.5), and median SCC interval between SCCs was 10.8
months (IQR 4.8–31.0).
Age- and sex-specific IRs
The age-standardized IR of persons newly affected was highest
in the BCC-only group (392 per 100,000 pyar) and lowest in
the SCC-only group (105 per 100,000 pyar) with the rate in the
mixed group being intermediate (189 per 100,000 pyar;
Table 1).
BCC only
The IR for men developing multiple BCC-only (503 per
100,000 pyar) was higher than that for women (361 per
100.000 pyar) (Table 1), but the difference in risk was not
statistically significant (relative risk (RR)¼1.41; 95% confi-
dence interval (CI)¼ 0.88–2.25) (Table 2). Age-specific IRs
increased with increasing age from 259 per 100,000 pyar for
people aged o40 years to 625 per 100,000 pyar for those
aged X60 years (Table 1), with a significant twofold
(RR¼ 2.35, CI¼ 1.18–4.68) increase in risk for participants
aged X60 years compared with those aged o40 years
(Table 2). Among those with at least two keratinocyte cancers,
88 people had a BCC first and 65 (74%) subsequently had
BCC exclusively.
SCC only
The IR for men developing multiple SCCs only (137 per
100,000 pyar) was similar to that in women (101 per 100,000
pyar) (Table 1) with no significant difference in RR (Table 2).
Incidence of people affected with multiple new SCCs
increased steeply with age, with no affected person under
40 years of age (Table 1), and people agedX60 years were at
more than six times the risk (RR¼6.44, 95% CI¼ 2.32–17.9)
of people aged 40–59 years (Table 2). Of the 28 who had SCC
first among those with multiple skin cancers, 18 (64%)
subsequently had SCC exclusively.
BCC and SCC
Among people affected by a mix of BCC and SCC, IRs were
the same for men (213 per 100,000 pyar) and women (214 per
100,000 pyar) (Table 1). Among those agedo40 years, IRs of
mixed tumors were lower than for multiple BCCs and
increased with age to 555 per 100,000 pyar in people aged
X60 years (Table 1), corresponding to a 13 times higher risk
(RR¼ 13.4; 95% CI¼ 3.11–57.9) (Table 2).
Clinical features
Although there were no significant differences in skin, eye or
hair color between the groups, 28% of those with only SCCs
had skin that sunburnt easily and did not tan and 22% tanned
without burning, compared with 12% and 2%, respectively, in
the BCC-only group, and 28% of the SCC-only group had
freckling of the back compared with 14% of the BCC-only
group (all Po0.05). Although prevalence of these features in
the mixed BCC–SCC group was intermediate, 45% of the
BCC–SCC group had medium skin color and 48% had severe
elastosis of the neck (assessed by a dermatologist) compared
with 39% of the SCC-only group with severe elastosis and
28% of the BCC-only group (Po0.001).
Person-specific proportional site distributions
The head and neck were the predominant sites of BCC among
those with multiple BCCs only (51%) and in those with both
BCC and SCC (56%), whereas the second commonest site in
the BCC-only group was the trunk and in the BCC–SCC group
the limbs (Figure 1a). In those with multiple SCCs only and
also those with both BCCs and SCCs, the predominant sites of
lesions were the limbs (54% and 49%, respectively), followed
by the head and the neck (38% and 35%) (Figure 1b).
Results did not differ materially when analyses were
repeated for individuals who had not been allocated to the
sunscreen intervention. This subgroup showed virtually the
same patterns of occurrence of BCC and SCC and similar IRs
as in the overall group (data not shown).
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DISCUSSION
The aim of this 16-year prospective study was to investigate
whether persons who are affected by more than one kerati-
nocyte skin cancer tend to develop exclusively BCC or
exclusively SCC over time, or a mix of both keratinocyte
cancers. In this Australian population sample of previously
unaffected people aged 46 years on average, the incidence in
the BCC-only group was over three times higher than in the
SCC-only group, broadly consistent with the BCC to SCC ratio
in the general population, whereas the incidence in the mixed
group was intermediate, as would be expected. Furthermore,
around 20% of this previously unaffected cohort developed a
BCC or SCC during follow-up, and among those who had a
first diagnosis 47% developed a subsequent primary keratino-
cyte cancer. We found that 56% of people who developed
more than one keratinocyte cancer developed BCC
exclusively, and 16% of people developed SCC exclusively
in the 16 years of observation. Only around a third developed
both BCC and SCC.
These findings are in line with anecdotal clinical observa-
tions that those who are multiply affected by skin cancer seem
to be prone to one particular type of keratinocyte cancer, and
that occurrence of BCC-only affected patients is not merely a
result of the higher IR of BCC compared with SCC. This type-
specific predilection may be the consequence of particular
genetic susceptibilities, especially for individuals in the BCC-
only group, who may carry mutations of genes in the Hedge-
hog pathway or sporadic variants of Patched or other germline
mutations (de la Fouchardiere et al., 2014). In those under
60 years of age, higher IRs of BCC-only than of mixed BCC-
SCC would reflect the higher rates of BCC in younger
adulthood. However, after the age of 60 years, observed
Table 1. Age- and sex-specific IRs of BCC and/or SCC in those with multiple lesions from 1992 to 2007 among 1,191
people observed
N Total pyar1 Mean pyar
Persons with 41 BCC, 0
SCC (N¼ 65)
Persons with 41 SCC, 0
BCC (N¼ 18)
Persons with X1 BCCþX 1
SCC (N¼33)
N IR 95% CI N IR 95% CI N IR 95% CI
Sex
Male 509 6,561 12.9 33 503 331–675 9 137 47–227 14 213 101–325
Female 682 8,872 13.0 32 361 236–486 9 101 35–167 19 214 118–310
Age group
o40 years 387 5,011 13.0 13 259 118–400 0 — — 2 40 0–95
40–59 years 573 7,541 13.2 34 451 299–603 5 66 8–124 15 199 99–299
X60 years 231 2,881 12.5 18 625 336–914 13 451 206–696 16 555 283–827
Weighted average2 392 105 189
Total 1,191 15,433 13.0 65 421 319–523 18 117 63–171 33 214 141–287
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; IR, incidence rate; pyar, person-years at risk; SCC, squamous-cell carcinoma.
1Per 100,000 person-years.
2Age standardized to the standard world population.
Table 2. RRs of BCC and SCC associated with sex and age in those with multiple lesions from 1992 to 2007 among
1,191 people observed
Persons with 41
BCC, 0 SCC (N¼ 65)
Persons with 41 SCC, 0
BCC (N¼ 18)
Persons with X1
BCCþX 1 SCC (N¼ 33)
RR1 95% CI P value RR 95% CI P value RR 95% CI P value
Sex (reference group: females)
Male 1.41 0.88–2.25 0.15 1.39 0.56–3.44 0.47 1.02 0.52–2.0 0.95
Age group Reference groups: o40 y 40–59 y o40 y
o40 y 1.00 n.a.2 1.00
40–59 y 1.79 0.96–3.33 0.07 1.00 5.07 1.17–22.0 0.03
X60 y 2.35 1.18–4.68 0.02 6.44 2.32–17.9 o0.001 13.41 3.11–57.9 0.001
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; RR, relative risk; SCC, squamous-cell carcinoma; y, year.
1Relative risk was adjusted for sex and age.
2No person in this age group.
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higher IRs of BCC-only than of mixed BCC-SCC do not accord
with the high age-specific incidence of SCC and BCC after the
age of 60 years (Green et al., 1996; Staples et al., 2006). That
is, on the basis of background IRs, one might predict that skin
cancer–susceptible people would be newly affected by both
BCC and SCC rather than by BCC exclusively after the age of
60 years.
As a corollary, the subgroup of individuals who developed
multiple SCCs exclusively over 16 years without developing
BCC is also unexpected, given the higher rates of BCC in every
age group in the general population. This SCC-only group is
likely to be a subgroup of individuals with very high
cumulative sun exposure who may be less genetically suscep-
tible to BCC than the BCC-only group. The 38% of people
with no history of skin cancer at baseline who newly
developed both BCC and SCC during follow-up showed a
much higher increase in risk after 60 years of age relative to
the 40–59-year age group, than the BCC-only group,
likely reflecting the very high age dependence of SCC. The
person-specific site distribution of BCC versus SCC among
people with both showed a convergence of the site distribu-
tions of BCC and SCC in persons with one or the other
exclusively.
Sex-specific IRs of BCC or SCC did not differ significantly
across all three study groups. Thus, these results do not to
support others’ findings of an increased risk of second and
subsequent (Graells, 2004; Richmond-Sinclair et al., 2010;
Flohil et al., 2011) BCCs among males but this most likely
reflects the exclusion of any person with a previous skin
cancer from our study, a large proportion of whom were male,
so that we could accurately capture the lifetime skin cancer
experience to date during follow-up.
Clinically, those with SCC exclusively comprised the most
distinctive group, with significantly higher prevalence of two
contrasting pigmentary characteristics than seen in the other
multiply affected groups, namely very high sunburn propensity
and propensity to tan without burning, as well as a high
prevalence of freckling of the back. These features are
correlated with the gross actinic damage associated with
cutaneous SCC, either because those who do not tan with
sun exposure receive large doses of solar ultraviolet radiation
at the dermo-epidermal junction or because those with darker
skin can tolerate very high cumulative sun exposure, e.g.,
through outdoor occupations. The high prevalence of severe
elastosis of the neck seen in the mixed group may reflect their
intermediate skin type, having some sensitivity to sun damage
combined with an ability to tan, rendering this group capable
of better tolerating the effects of high cumulative sun exposure
than the very sunburn-prone.
The highly selected nature of the restricted study sample
was the major weakness of this analysis; however, as above, it
was necessary to allow us to test the null hypothesis of no
exclusive clustering of BCC or of SCC in skin cancer–
susceptible individuals. Although the patterns of exclusivity
of skin cancer types in newly affected persons should be
generalizable, the specific IRs seen in those with BCC-only
and SCC-only in our selected study cohort would not
represent the rates observed if it were possible to follow a
younger cohort of adults over their lifetimes. Relatively small
sample sizes within the subgroups, especially the SCC-only
group, were a further limitation. The strengths of this study on
the other hand were its prospective design and its community-
based sample, with complete ascertainment of all histological
confirmed BCCs and SCCs and high follow-up rate in a 16-
year period.
Direct comparison of these results with other studies is not
possible because the question of exclusivity of skin cancer
types in the general population has not been addressed before.
Most of the epidemiological studies of people with multiple
keratinocyte cancers have investigated the incidence of a
second lesion following an index lesion but have not estab-
lished the risk of developing BCC or SCC lesions exclusively
beyond their second skin cancer. However, our findings are
consistent with the pooled observations of previous studies,
mostly in clinical populations, that patients’ second skin
cancer at least is likely to be the same type as the index
cancer: patients with a BCC had a 17 times increased risk of
developing a BCC subsequently compared with the BCC risk
in the general population, and SCC patients had 4 times the
risk of developing a subsequent SCC compared with the
general population (Flohil et al., 2013).
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Figure 1. Average person-specific proportional site distributions of BCC and
SCC. (a) Distribution of basal cell carcinoma (BCC) lesions among people with
no past skin cancer who developed BCCs exclusively and those who
developed BCCs and SCCs from 1992 to 2007. (b) Distribution of squamous-
cell carcinoma (SCC) lesions among people with no past skin cancer who
developed SCCs exclusively and those who developed BCCs and SCCs from
1992 to 2007.
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The anatomic site distribution of the different skin cancer
types within individual people has not been described earlier
either. Three case–control studies have evaluated the risk
factors for BCC and SCC in the same population simulta-
neously, but differential clustering of lesions was not assessed
(Dubin et al., 1990; Han et al., 2006; Zanetti et al., 2006). A
previous analysis of the Nambour Skin Cancer Study also with
a follow-up time of 16 years investigated IRs of multiple
BCCs, but no particular account was taken of previous skin
cancer history, and co-occurrence of SCC in affected people
was not considered (Richmond-Sinclair et al., 2010).
Although the 5-year follow-up study carried out by Karagas
et al. (1992) did distinguish between patients affected by BCC
only, SCC only, and those with a combination of both,
patients with a past skin cancer were not excluded, and
thus lifetime exclusivity for type-specific groups was not
established. While a clinic-based study conducted in renal
transplant recipients (Wisgerhof et al., 2010) recorded all skin
cancers developed by newly affected patients during a
follow-up period, exclusivity of cancer types in those with
several cancers was not evaluated beyond the second skin
cancer, although immunosuppressed patients’ tendency to
develop one skin cancer type rather than a mix was consistent
with our results in the general population.
In conclusion, this study showed that a substantial propor-
tion of the general population aged around 45 years on
average develop BCCs exclusively after developing a first
BCC, and a smaller proportion who develop SCC as their first
skin cancer go on to develop only SCCs subsequently. An
intermediate proportion of newly affected people developed
both BCC and SCC during follow-up. Large prospective
population-based studies need to be conducted from early
adulthood to extend these results. If our findings are replicated
and the existence of type-specific skin cancer susceptibility is
confirmed, it would have major therapeutic implications
whereby tailored treatments could be developed and applied
collectively rather than individually to skin cancers—for
example, in BCC-prone people if found to have certain genetic
predispositions. Physicians would have better prognostic
information to give patients, and they could better plan the
management of type-specific patients, for example, with
regular surveillance of BCC- or SCC-prone anatomic subsites
and intensified follow-up of SCC-prone patients. The latter
group would be strongly counseled about ongoing effective
sun protection such as regular sunscreen application (van der
Pols et al., 2006). Finally, there is heuristic value in identifying
that people may be affected exclusively by BCC or SCC, as
these patient groups would then offer new opportunities for
targeted etiologic research.
MATERIALS AND METHODS
Study participants
We conducted this 16-year prospective cohort study among adults
originally selected at random in 1986 from residents of Nambour, a
subtropical community in Australia (Green et al., 1988). Of the
original 2,095 adults aged 20–69 years in 1986, 1,621 participated in
a field trial between 1992 and 1996 that evaluated the effectiveness
of b-carotene supplementation and daily application of sunscreen in
preventing skin cancer (Green et al., 1994, 1999). Detailed
descriptions of the community sample, the trial, and its outcomes
have been reported previously (Green and Battistutta, 1990; Green
et al., 1996, 1999).
Data collection and follow-up
Between 1992 and 1996, all study participants underwent at least two
full-body skin examinations. Every 3 months, participants were
followed up in study clinics and asked about any skin cancers treated
since last contact. Information on skin cancer history before 1992 was
based on surveys conducted among the participants between 1986
and 1992 (Green et al., 1988, 1994, 1999) and on self-reports of any
keratinocyte cancer before 1986 (Green et al., 1988), with
histological verification of the subset of cancers reported in 1985–
1986 (Green and Battistutta, 1990).
On trial conclusion in 1996, participants were invited to take part
in a follow-up study until 2007 (Richmond-Sinclair et al., 2010). From
1996, treatment of any skin lesion was reported via annual or
biannual questionnaires, and all self-reported BCCs and SCCs were
confirmed by reviewing medical records. Further full-body skin
examinations were conducted in 2000 and 2007. During the com-
plete follow-up period from 1992 to 2007, independent pathology
laboratories in Queensland provided pathology reports for all skin
cancers diagnosed among the study cohort (Valery et al., 2004). Thus,
there was complete ascertainment of all histopathologically confir-
med BCCs and SCCs for the study population for the period 1992–
2007. The study was approved by the Ethics committee of the QIMR
Berghofer Medical Research Institute, and all participants provided
written informed consent.
Statistical analysis
We restricted the current analyses to Nambour Study participants of
white Caucasian ethnicity and excluded those with any keratinocyte
cancer before or at the start of the study in 1992. No study participants
had nevoid BCC (Gorlin) syndrome or were immunosuppressed.
In assessing people’s first and subsequent incident lesions within
the 16-year follow-up period, we classified them into three groups:
those who developed BCCs only, those who developed SCCs only,
and those affected by both BCC and SCC (simultaneously or over
time). We calculated person-based age- and sex-specific IRs for each
group by dividing the number of persons with a histological
diagnosis of BCC or SCC by the total number of pyar for the
observed period, expressed per 100,000 pyar. Person-years
were counted until the date of death, date of withdrawal from the
study, or the end date of observation, whichever came first. IRs
were directly age-standardized to the standard world population.
Age at baseline was categorized into three groups (o40 years, 40–59
years, and X60 years).
RRs and 95% CIs for age-and sex-specific IRs were estimated by
multivariate Poisson regression. All persons were counted only once
in order to maintain the independence of the observations.
To describe the different site patterns of BCCs and SCCs within
individuals and to identify the predominant lesion site for each of the
three groups, we calculated person-specific proportional lesion
distributions and took the average of these proportions over all study
participants within each study group (multiple BCCs only, multiple
SCCs only, and the mixed group). Lesions were categorized as
occurring on the head and neck, limbs, or trunk.
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As regular sunscreen use has been shown to diminish the incidence
of SCCs (Green et al., 1999), we repeated the analyses for the 592
persons who were not allocated to the sunscreen intervention during
the Nambour trial and compared the results with the entire study
population.
Statistical analyses were conducted using SAS version 9.2 (SAS
Institute, Cary, NC). P-values were two sided and Po0.05 was
considered statistically significant.
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